Clinical trial · Observational
Gut Microbiome in DLBCL Treated With Glofitamab
Role of the Gut Microbiome in the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated With Glofitamab
NCT07498920CI-TRIAL-00106527not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The gut microbiome (GM) has recently emerged as one of the key modifiable factors of response and prognosis to immunotherapy in cancer patients. Currently, it is unknown if GM also modulates anti-tumor responses to T cell engagers (TCE) including glofitamab in DLBCL patients.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| DLBCL | Diffuse Large B-Cell Lymphoma | ALIAS | 0.90 |
| Glofitamab | — | UNRESOLVED | — |
| Gut Biome | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gut microbiome analysis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- GM group
- interventionNames
- Other: Gut microbiome analysis
Primary outcomes (1)
- measure
- Changes in gut microbiome
- timeFrame
- 2 years
- description
- Characterization of the compositional and functional modifications of gut microbiome in DLBCL patients treated with glofitamab from baseline to 1 year after the end of treatment.
Secondary outcomes (1)
- measure
- Correlation between gut microbiome and therapy outcomes in terms of response and toxicity
- timeFrame
- 2 years
- description
- Correlation between gut microbiome and therapy outcomes in terms of response and toxicity
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Histologically/cytologically confirmed diagnosis of DLBCL 2. Is being planned to received Glofitamab 3. Be able to provide written informed consent Exclusion Criteria: 1. Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results. 2. Concurrent second malignancy.
References
Publications (0)
Data not yet available
No reference posted for this study.